Synonyms: NS-018 | NS018
Compound class:
Synthetic organic
Comment: Ilginatinib (NS-018) is a potent and highly selective JAK2 inhibitor. It has an ATP-competitive mode of action. The chemical structure shown here was rendered from the chemical name provided in [1]. The inhibits some Src family kinases in addition to JAK2 [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Ilginatinib (NS-018) was advanced as a clinical lead. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT01423851 | Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF | Phase 1/Phase 2 Interventional | NS Pharma, Inc. | Results from the Phase 1 portion of this trial were published in 2017. Significant reduction in palpable spleen size and improvements in myelofibrosis-associated symptoms were observed. | 3 |
NCT04854096 | Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis | Phase 2 Interventional | NS Pharma, Inc. | 3 |